Soc. Generale Knock-Out Genmab AS/ DE000SU2XVD1 /
30.05.2024 8:24:50 | Изменение-0.11 | Бид8:59:48 | Предложение8:59:48 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
9.51EUR | -1.14% | 9.50 Величина цены спроса: 500 |
9.80 Величина цены предложения: 500 |
- | 1,217.7494 DKK | 31.12.2078 | Call |
GlobeNewswire
9:01
Persistent Systems Selects Zscaler to Launch Technology Modernization and Renewable Energy Initiativ...
GlobeNewswire
9:00
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer I...
GlobeNewswire
9:00
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutrace...
GlobeNewswire
8:35
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
GlobeNewswire
8:30
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimi...
GlobeNewswire
8:30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
8:30
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
GlobeNewswire
8:30
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница